Lok Sabha passes the The Regional Centre for Biotechnology Bill, 2016

The Bill seeks to establish a Regional Centre for Biotechnology, an institution of education, training and research, under the auspices of UNESCO

id-100291887

The Regional Centre for Biotechnology will take up research and innovation and impart education and training in the new areas of Biotechnology

The Lower House of the Parliament passed The Regional Centre for Biotechnology Bill, 2016. The Bill seeks to establish a Regional Centre for Biotechnology, an institution of education, training and research, under the auspices of United Nations Educational, Scientific and Cultural Organization (UNESCO) in the National Capital Region and declare it to be an institution of national importance.

The Regional Centre for Biotechnology will take up research and innovation and impart education and training in the new areas of Biotechnology at the interface of multiple disciplines of science creating a hub of technology expertise.

Speaking on the floor of the House, Union Minister of Science & Technology and Earth Sciences, Dr Harsh Vardhan said that Bio-technology is a new and growing field having immense potentialities for the societal benefit and economic transformation. It has been considered as a powerful enabling technology that can revolutionize agriculture, healthcare, industrial processing and environmental sustainability.

Noting the immense potential of the Bio-technology sector in India, he said that this sector is one of the fastest growing knowledge-based sectors and the Indian biotech industry grew threefold in just five years. With numerous comparative advantages in terms of research and development (R&D) facilities, knowledge, skills, and cost effectiveness, the biotechnology industry in India has immense potential to emerge as a global key player. A rich and varied bio-diversity, a flourishing pharmaceutical industry, strong IT skills have also provided favourable environment.

India is now a leading manufacturer of vaccines at an affordable cost, for example, making a recombinant DNA Hepatitis-B vaccine available at a price that is 40 times lower with such a high quality that it has captured major share of this market. Thanks to the huge human resource with excellent training in synthetic chemistry, India has also made major in-roads in generic drug production becoming the leader in the sector, he added.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X